Cas:74551-31-8 D-Valyl-L-phenylalanyl-N-(4-nitrophenyl)-L-lysinamide dihydrochloride manufacturer & supplier

Chemical Name:D-Valyl-L-phenylalanyl-N-(4-nitrophenyl)-L-lysinamide dihydrochloride

CAS.NO:74551-31-8

Synonyms:D-Val-Phe-Lysp-Nitroanilide2HCl;D-VAL-PHE-LYS4-NITROANILIDEDIHYDROCHLORIDE;D-VAL-PHE-LYS P-NITROANILIDE*DIHYDROCHLO RIDE;H-D-Val-Phe-Lys-pNA-2HCl

Molecular Formula:C₂₆H₃₈Cl₂N₆O₅

Molecular Weight:585.52300

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:185.16000

Exact Mass:584.22800

LogP:6.24050

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like D-Val-Phe-Lysp-Nitroanilide2HCl chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,H-D-Val-Phe-Lys-pNA-2HCl physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,D-VAL-PHE-LYS P-NITROANILIDE*DIHYDROCHLO RIDE Use and application,H-D-Val-Phe-Lys-pNA-2HCl technical grade,usp/ep/jp grade.

Related News: If an API is not ultrapure, a medicine cannot meet the strict quality criteria so the quality of an API plays a very important role. D-Valyl-L-phenylalanyl-N-(4-nitrophenyl)-L-lysinamide dihydrochloride manufacturer If an API is not ultrapure, a medicine cannot meet the strict quality criteria so the quality of an API plays a very important role. D-Valyl-L-phenylalanyl-N-(4-nitrophenyl)-L-lysinamide dihydrochloride supplier One source familiar with the matter told Reuters that the J&J doses are expected to be exported to other countries. The doses are already in vials and ready for use, the other source said. D-Valyl-L-phenylalanyl-N-(4-nitrophenyl)-L-lysinamide dihydrochloride vendor Our previous work with Retrogenix validated their technology as a uniquely powerful approach for antibody target deconvolution, and we look forward to working with Retrogenix to enhance our growing pipeline of antibody candidates.�� D-Valyl-L-phenylalanyl-N-(4-nitrophenyl)-L-lysinamide dihydrochloride factory He said the FDA made its decision by fiat, and had not asked its advisors to consider whether the drug’s ability to remove a type of brain plaques known as beta amyloid would improve outcomes for patients.